Kevin Feeley Sells 370 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 370 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $71.26, for a total transaction of $26,366.20. Following the sale, the chief financial officer now directly owns 4,105 shares in the company, valued at approximately $292,522.30. This trade represents a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, April 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $113.09, for a total value of $43,878.92.
• On Wednesday, April 9th, Kevin Feeley sold 15,516 shares of GeneDx stock. The shares were sold at an average price of $92.18, for a total value of $1,430,264.88.
• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The shares were sold at an average price of $95.61, for a total value of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total transaction of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The stock was sold at an average price of $94.72, for a total transaction of $87,331.84.

GeneDx Stock Performance

NASDAQ:WGS opened at $72.39 on Thursday. The firm has a market cap of $2.07 billion, a PE ratio of -36.93 and a beta of 1.96. GeneDx Holdings Corp. has a fifty-two week low of $23.88 and a fifty-two week high of $117.75. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The business has a 50 day moving average price of $80.52 and a 200-day moving average price of $82.12.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.17. The firm had revenue of $87.12 million during the quarter, compared to analyst estimates of $79.90 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. Equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Institutional Trading of GeneDx

A number of institutional investors have recently made changes to their positions in the stock. William Blair Investment Management LLC purchased a new stake in GeneDx in the fourth quarter worth $51,496,000. Lord Abbett & CO. LLC purchased a new stake in GeneDx in the fourth quarter worth $48,458,000. Summit Partners Public Asset Management LLC lifted its stake in GeneDx by 336.9% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after acquiring an additional 582,619 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in GeneDx in the first quarter worth $44,614,000. Finally, Alliancebernstein L.P. lifted its stake in GeneDx by 3,054.5% in the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock worth $38,694,000 after acquiring an additional 423,050 shares during the period. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

WGS has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of GeneDx in a research report on Thursday, May 15th. They issued a “buy” rating and a $88.00 price objective on the stock. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. TD Securities decreased their price objective on shares of GeneDx from $135.00 to $110.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company reduced their price target on shares of GeneDx from $105.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 1st. Finally, Jefferies Financial Group upgraded shares of GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Friday, May 9th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.75.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.